Page last updated: 2024-08-26

sr141716 and Sensation Disorders

sr141716 has been researched along with Sensation Disorders in 1 studies

Research

Studies (1)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	1 (100.00)	29.6817
2010's	0 (0.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Ballmaier, M; Bortolato, M; Gessa, G; Heinz, A; Rizzetti, C; Spano, P; Zoli, M	1

Other Studies

1 other study(ies) available for sr141716 and Sensation Disorders

Article	Year
Cannabinoid receptor antagonists counteract sensorimotor gating deficits in the phencyclidine model of psychosis. Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology, 2007, Volume: 32, Issue:10 Topics: Animals; Brain; Cannabinoid Receptor Antagonists; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Interactions; Drug Synergism; Excitatory Amino Acid Antagonists; Glutamic Acid; Male; Phencyclidine; Piperidines; Psychoses, Substance-Induced; Pyrazoles; Rats; Receptors, Cannabinoid; Reflex, Startle; Rimonabant; Schizophrenia; Sensation Disorders; Synaptic Transmission	2007

Article

Year

Cannabinoid receptor antagonists counteract sensorimotor gating deficits in the phencyclidine model of psychosis.

Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology, 2007, Volume: 32, Issue:10

Topics: Animals; Brain; Cannabinoid Receptor Antagonists; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Interactions; Drug Synergism; Excitatory Amino Acid Antagonists; Glutamic Acid; Male; Phencyclidine; Piperidines; Psychoses, Substance-Induced; Pyrazoles; Rats; Receptors, Cannabinoid; Reflex, Startle; Rimonabant; Schizophrenia; Sensation Disorders; Synaptic Transmission

2007